Skip to content

Partnerships

Microscopic illustration of a cell with internal structures visible

Incisive Genetics is advancing a non-viral delivery system designed to overcome key biological and translational limitations of current gene editing approaches. Our proprietary LNP platform enables the delivery of pre-formed CRISPR RNP complexes to unlock efficient, repeatable, and titratable in vivo gene editing across multiple disease areas.

An advanced delivery technology for in vivo gene editing

By delivering the active ribonucleoprotein complex rather than genetic instructions, our platform increases editing efficiency while reducing prolonged nuclease exposure.

This design provides a strategic advantage in complex genetic diseases where controlled editing and safety margins are critical.

Learn more about our technology
Viral Gene Therapy

Single high-dose exposure
Intracellular protein translation required
Prolonged nuclease expression
Limited cargo flexibility

VS

Incisive Genetics non-viral LNP-RNP Platform

Repeat dosing capability
Functional RNP delivered ready to edit
Rapid clearance
Enables multiple guides + DNA template

Family smiling and playing together indoors

Proven in Huntington’s disease. Adaptable across tissues and genetic targets

Our lead program in Huntington’s disease demonstrates the clinical intent of the platform: selective excision of pathogenic DNA while preserving normal genetic function.

While Huntington’s disease is our initial clinical focus, the underlying LNP-RNP delivery architecture is adaptable across tissues and genetic indications. By modifying guide sequences and DNA templates, the platform can be tailored to address diverse monogenic disorders.

In addition, LNP composition and particle characteristics can be engineered to optimize biodistribution and tissue-directed delivery across multiple organ systems.

View our Science
Microscopic illustration of a cell with internal structures visible

Our technology is built for translation and scale

Incisive Genetics’ platform is engineered with a clear goal of translating gene editing into clinically meaningful therapies.

  • Worldwide patents granted
  • Unencumbered IP portfolio
  • Established LNP chemistries
  • cGMP process development underway
  • Scalable manufacturing strategy
Microscopic illustration of a protein complex suspended in fluid

Accelerating curative gene editing therapeutics

Whether your focus is to expand a gene editing pipeline, overcome delivery constraints, or advance your complex DNA-targeted therapy, Incisive Genetics’ proprietary LNP-RNP platform provides a best-in-class solution for in vivo genome modification.

Reach out to explore platform partnerships, co-development agreements, or strategic investment discussions.

Get in Touch
Top